Use of ventricular enlargement rate in intravenous...

Details Use of ventricular enlargement rate in intravenous... Use of ventricular enlargement rate in intravenous...

2011-04-13

2011-11-29

Spector, Lorraine (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S142100, C514S017800, C530S387100

Reexamination Certificate

active

08066993

ABSTRACT:
The present invention relates to the use of MRI monitoring of ventricular enlargement rate as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen for Alzheimer's patients. Methods for treating Alzheimer's Disease and monitoring therapeutic effectiveness are provided.

REFERENCES:
patent: 2009/0155256 (2009-06-01), Black et al.
patent: WO 2009/017467 (2009-02-01), None
Dodel et al., Drugs, 70(5):513-528, Mar. 26, 2010.
Salloway et al. Neurology 73:2061-2070, 2009.
Fox et al., “Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease,” 2005, Neurology, 64, pp. 1563-1572.
Gilman et al., “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial,” 2005, Neurology, 64, 1553-1562.
Jack et al. “MRI as a Biomaker of Disease Progression in a Therapeutic Trial of Milameline for AD,” 2003, Neurology, 60(2); pp. 253-260.
Krishman et al., “Randomized, Placebo-Controlled Trial of the Effects of Donepezil and Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease,” 2003, Am. J. Psychiatry, 160: 11: pp. 2003-2011.
Mueller et al., “Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS,” 2006, NMR Biomed., 16(6), pp. 655-668.
Ridha et al., “Volumetric MRI and cognitive measures in Alzheimer's disease,” 2008, J. Neurol. 255: 567-574.
Tsakanikas et al., “Effects of uninterrupted intravenous immunoglobulin treatment of Alzheimer's disease for 9 months,” 2008, presented at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), Chicago, IL, ICAD-2008; Abstract 08-A3147.
International Search Report and Written Opinion dated Jun. 24, 2011, issued in related International Application No. PCT/US2011/032232, filed Apr. 13, 2011.
Nestor et al., “Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database,” 2008, Brain, 131, pp. 2443-254.
Evans et al., “IVIG Reduced Brain Atrophy in Alzheimer's,” Clinical Psychiatry News [online], Jun. 2010 [retrieved on Jun. 10, 2010]. Retrieved from the internet: <URL : http://psych.imng.com/fileadmin/content—pdf/cpn/archive—pdf/vol38iss6/70262—main.pdf].

Affiliated with

Also associated with

Rating

Use of ventricular enlargement rate in intravenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of ventricular enlargement rate in intravenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ventricular enlargement rate in intravenous... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308423